Skip to main content
. 2022 Jun;63(6):862–868. doi: 10.2967/jnumed.121.263016

FIGURE 5.

FIGURE 5.

(A) Ex vivo biodistribution of 68Ga-FAPI-46 in HCC-PDX-1, 1 and 4 h after injection (n = 3/group). (B) Ex vivo biodistribution of 68Ga-DOTA-2P(FAPI)2 in HCC-PDX-1, 1 and 4 h after injection, with and without coadministration of unlabeled FAPI-46 as blocking agent (n = 3/group).